FI4225351T1 - Koostumus ja menetelmä syövän hoitamiseksi käyttämällä rokotetta ensimmäisenä terapeuttisesti aktiivisena ainesosana yhdessä toisen aktiivisen ainesosan kanssa - Google Patents
Koostumus ja menetelmä syövän hoitamiseksi käyttämällä rokotetta ensimmäisenä terapeuttisesti aktiivisena ainesosana yhdessä toisen aktiivisen ainesosan kanssa Download PDFInfo
- Publication number
- FI4225351T1 FI4225351T1 FIEP21880926.7T FI21880926T FI4225351T1 FI 4225351 T1 FI4225351 T1 FI 4225351T1 FI 21880926 T FI21880926 T FI 21880926T FI 4225351 T1 FI4225351 T1 FI 4225351T1
- Authority
- FI
- Finland
- Prior art keywords
- vaccine
- hpv
- inhibitor
- dose
- therapeutic agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 27
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 239000000203 mixture Substances 0.000 title claims 9
- 229960005486 vaccine Drugs 0.000 title claims 7
- 239000004480 active ingredient Substances 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229960002566 papillomavirus vaccine Drugs 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 4
- 229950002916 avelumab Drugs 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 229940124551 recombinant vaccine Drugs 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229940112129 campath Drugs 0.000 claims 2
- 229960000419 catumaxomab Drugs 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229950001969 encorafenib Drugs 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims 1
- 229960004449 vismodegib Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/068,087 US11813329B2 (en) | 2014-10-24 | 2020-10-12 | Method and composition for treating cancer or skin lesion using a vaccine |
PCT/US2021/054622 WO2022081604A1 (en) | 2020-10-12 | 2021-10-12 | Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
FI4225351T1 true FI4225351T1 (fi) | 2023-10-20 |
Family
ID=81208565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FIEP21880926.7T FI4225351T1 (fi) | 2020-10-12 | 2021-10-12 | Koostumus ja menetelmä syövän hoitamiseksi käyttämällä rokotetta ensimmäisenä terapeuttisesti aktiivisena ainesosana yhdessä toisen aktiivisen ainesosan kanssa |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4225351A1 (ko) |
JP (1) | JP2023546073A (ko) |
KR (1) | KR20230117106A (ko) |
AU (1) | AU2021360676A1 (ko) |
CA (1) | CA3195478A1 (ko) |
CO (1) | CO2023006083A2 (ko) |
CY (1) | CY20232200001T2 (ko) |
DE (1) | DE21880926T1 (ko) |
DK (1) | DK4225351T1 (ko) |
ES (1) | ES2962700T1 (ko) |
FI (1) | FI4225351T1 (ko) |
HU (1) | HUE21880926T1 (ko) |
IL (1) | IL302098A (ko) |
MX (1) | MX2023004285A (ko) |
PL (1) | PL4225351T1 (ko) |
WO (1) | WO2022081604A1 (ko) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
US20150148423A1 (en) * | 2012-04-26 | 2015-05-28 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
US10799574B2 (en) * | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
MX2018012017A (es) * | 2016-04-01 | 2019-07-04 | Kite Pharma Inc | Antigeno quimerico y receptores de celulas t y metodos de uso. |
AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
-
2021
- 2021-10-12 IL IL302098A patent/IL302098A/en unknown
- 2021-10-12 DK DK21880926.7T patent/DK4225351T1/da unknown
- 2021-10-12 AU AU2021360676A patent/AU2021360676A1/en active Pending
- 2021-10-12 DE DE21880926.7T patent/DE21880926T1/de active Pending
- 2021-10-12 FI FIEP21880926.7T patent/FI4225351T1/fi unknown
- 2021-10-12 JP JP2023522489A patent/JP2023546073A/ja active Pending
- 2021-10-12 PL PL21880926.7T patent/PL4225351T1/pl unknown
- 2021-10-12 KR KR1020237016232A patent/KR20230117106A/ko unknown
- 2021-10-12 WO PCT/US2021/054622 patent/WO2022081604A1/en active Application Filing
- 2021-10-12 HU HUE21880926A patent/HUE21880926T1/hu unknown
- 2021-10-12 ES ES21880926T patent/ES2962700T1/es active Pending
- 2021-10-12 EP EP21880926.7A patent/EP4225351A1/en active Pending
- 2021-10-12 CA CA3195478A patent/CA3195478A1/en active Pending
- 2021-10-12 MX MX2023004285A patent/MX2023004285A/es unknown
-
2023
- 2023-05-12 CO CONC2023/0006083A patent/CO2023006083A2/es unknown
- 2023-10-19 CY CY20232200001T patent/CY20232200001T2/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP4225351A1 (en) | 2023-08-16 |
WO2022081604A1 (en) | 2022-04-21 |
JP2023546073A (ja) | 2023-11-01 |
IL302098A (en) | 2023-06-01 |
DK4225351T1 (da) | 2023-10-23 |
AU2021360676A1 (en) | 2023-06-15 |
ES2962700T1 (es) | 2024-03-20 |
MX2023004285A (es) | 2023-06-19 |
CA3195478A1 (en) | 2022-04-21 |
CY20232200001T2 (el) | 2024-02-16 |
PL4225351T1 (pl) | 2023-12-11 |
HUE21880926T1 (hu) | 2024-04-28 |
CO2023006083A2 (es) | 2023-08-18 |
KR20230117106A (ko) | 2023-08-07 |
DE21880926T1 (de) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2684569A1 (en) | A composition for treatment of advanced prostate cancer | |
KR100861466B1 (ko) | 항혈관형성제 및 TNFα를 이용한 병용 요법 | |
KR20040007413A (ko) | 단기 및 장기 약물 약량측정 방법 | |
US7141550B2 (en) | Intra-tumoral administration of IL-12 encoding nucleic acid molecules | |
US20230270824A1 (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
KR20210142663A (ko) | 암을 치료하기 위하여 iRGD와 공동 투여되는 저용량 사이토카인 | |
Tang et al. | Pharmacokinetics of peptides and proteins | |
FI4225351T1 (fi) | Koostumus ja menetelmä syövän hoitamiseksi käyttämällä rokotetta ensimmäisenä terapeuttisesti aktiivisena ainesosana yhdessä toisen aktiivisen ainesosan kanssa | |
EP2663324B1 (en) | Combination therapy for treating prostate cancer | |
US20100197595A1 (en) | Treatment of melanoma with alpha thymosin peptides | |
EP4282426A1 (en) | Method and pharmaceutical combination for preventing cancer recurrence | |
CA2832376C (en) | Drug containing recombinant mistletoe lectins for treating malignant melanoma | |
JP2024504341A (ja) | 癌を治療するためのインターフェロンベースの方法及び組合せ医薬 | |
KR101482957B1 (ko) | 상피 성장 인자 수용체 항체에 대항하는 항체 치료의 효과를 개선하기 위한 치료 조성물 | |
Holgate | Penicillin allergy: how to diagnose and when to treat | |
Brzoska et al. | Immunomodulating effects of interferons: conclusions for therapy | |
Tanigawa et al. | Gene gun application in the generation of effector T cells for adoptive immunotherapy | |
AU2017218918B2 (en) | Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders | |
Smalley et al. | Interferons: current status and future directions of this prototypic biological | |
AU2011249040B2 (en) | Therapeutic peptide composition and method | |
JP2020500881A (ja) | Pd−1シグナル伝達を調節するための組成物 | |
Shau et al. | Regulation of NK Cytotoxicity In Vivo in Patients Receiving IL-2 | |
JP2023536460A (ja) | がんの処置のための併用療法 | |
Kushwaha | Immunomodulators as therapeutic agent | |
Wilkinson et al. | Use of biological response modifiers for management of renal cell carcinoma |